To match an exact phrase, use quotation marks around the search term. eg. "Parliamentary Estate". Use "OR" or "AND" as link words to form more complex queries.


Keep yourself up-to-date with the latest developments by exploring our subscription options to receive notifications direct to your inbox

Written Question
Metabolic Dysfunction-associated Steatohepatitis
Wednesday 18th November 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps she is taking to ensure that NHS services have the capacity and diagnostic infrastructure required to identify and treat people eligible for future NICE-recommended treatments for metabolic dysfunction-associated steatohepatitis.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

Further to the answer of 6 February in response to Question 106401, the National Institute for Health and Care Excellence (NICE) is evaluating resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis. No final guidance has yet been published, but NHS England has undertaken a system readiness assessment for both treatments, the findings of which have been submitted to NICE as part of the appraisal process.

This assessment recognises that there is strong clinical expertise within specialist liver services, but that wider readiness will depend on capacity and pathway planning, particularly for non-invasive diagnostic testing. Provision of diagnostics such as FibroScan, Enhanced Liver Fibrosis testing, Intelligent Liver Function Testing and use of FIB-4 scores currently vary across regions, and addressing this variation is a key focus of NHS preparation.

If NICE recommends these treatments, NHS England would implement them in line with national guidance and clinical prioritisation. Given the likely size of the eligible population and current diagnostic constraints, implementation may be phased and prioritised to ensure patient safety, equity of access and service sustainability. Initial prescribing and early treatment management would be led by specialist hepatology or gastroenterology services, supported by specialist nurses, with training supplied to primary care providers.

The Department and NHS England will continue to work to ensure that, if approved, these treatments are introduced in a way that is fair, affordable and protects the wider NHS, while ensuring that patients with the greatest clinical need benefit as quickly as possible.


Written Question
Metabolic Dysfunction-associated Steatohepatitis
Wednesday 18th November 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure consistent access across England to any NICE-recommended pharmacological treatments for metabolic dysfunction-associated steatohepatitis.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

Further to the answer of 6 February in response to Question 106401, the National Institute for Health and Care Excellence (NICE) is evaluating resmetirom and semaglutide for treating metabolic dysfunction-associated steatohepatitis. No final guidance has yet been published, but NHS England has undertaken a system readiness assessment for both treatments, the findings of which have been submitted to NICE as part of the appraisal process.

This assessment recognises that there is strong clinical expertise within specialist liver services, but that wider readiness will depend on capacity and pathway planning, particularly for non-invasive diagnostic testing. Provision of diagnostics such as FibroScan, Enhanced Liver Fibrosis testing, Intelligent Liver Function Testing and use of FIB-4 scores currently vary across regions, and addressing this variation is a key focus of NHS preparation.

If NICE recommends these treatments, NHS England would implement them in line with national guidance and clinical prioritisation. Given the likely size of the eligible population and current diagnostic constraints, implementation may be phased and prioritised to ensure patient safety, equity of access and service sustainability. Initial prescribing and early treatment management would be led by specialist hepatology or gastroenterology services, supported by specialist nurses, with training supplied to primary care providers.

The Department and NHS England will continue to work to ensure that, if approved, these treatments are introduced in a way that is fair, affordable and protects the wider NHS, while ensuring that patients with the greatest clinical need benefit as quickly as possible.


Written Question
Liver Diseases: Health Services
Monday 9th November 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps her Department is taking to ensure that liver disease prevention and early detection are included in plans to reduce ill-health-related economic inactivity.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

NHS England’s Liver Disease Programme includes work on early detection of liver damage and action to be taken to prevent its progression. I refer the Hon. Member to the answer provided on 18 September in response to Question 27776 about the NHS Liver Disease Programme, which includes a reference to the answer provided on 20 July in response to Question 17757.


Written Question
UK Biobank: Liver Cancer
Thursday 29th October 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment has been made of the potential merits of a national biobank linked to a national surveillance database for research and for improving the quality of surveillance for liver cancer patients.

Answered by James Frith - Parliamentary Under-Secretary (Department of Health and Social Care)

No assessment has been made.


Written Question
Liver Diseases: Diagnosis
Thursday 15th October 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of the ongoing restructuring of Integrated Care Boards on commissioned pathways for the early detection of liver disease.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

The specific data requested by the Hon Member is not centrally held, but he may find useful data on the prevalence and treatment of liver disease at local level via the Department’s Fingertips website at the following link:

https://fingertips.phe.org.uk/profile/liver-disease

On the broader issues raised, I refer the Hon Member to the answer provided on 18 September in response to Question 27776.


Written Question
Liver Diseases: Health Services
Thursday 15th October 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, if she will provide a breakdown by Integrated Care Board of the proportion of patients presenting with liver disease at a late stage.

Answered by Diana Johnson - Minister of State (Department of Health and Social Care)

The specific data requested by the Hon Member is not centrally held, but he may find useful data on the prevalence and treatment of liver disease at local level via the Department’s Fingertips website at the following link:

https://fingertips.phe.org.uk/profile/liver-disease

On the broader issues raised, I refer the Hon Member to the answer provided on 18 September in response to Question 27776.


Written Question
Kidney Diseases: Dialysis Machines
Monday 16th March 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 9 February 2026 to Question 110360 on kidney diseases: dialysis machines, what steps is the government taking to remove variation in rates of home dialysis in paediatric dialysis centres.

Answered by Sharon Hodgson

NHS England is delivering a comprehensive programme to improve the diagnosis, treatment, and outcomes of people with kidney disease, through its renal services transformation programme. This includes a specification for renal services which sets out the scope for the work of the renal clinical networks commissioned across England. The specification is available at the following link:

https://www.england.nhs.uk/wp-content/uploads/2024/05/PRN231110-renal-clinical-network-specification-2023-.pdf

The goals of the specification include reducing variation across the renal care pathway by developing, agreeing and implementing standardised pathways of care, including dialysis and home therapy services for adult and paediatric services. The eight regional kidney networks in England, working with providers, will review service delivery across network against need and identify gaps and variation in services, gaps in overall provision, quality, geographical distribution, and deliver improvements to network services to address these issues.


Written Question
Kidney Diseases: Dialysis Machines
Monday 9th February 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment his Department has made of levels of current capacity for in-centre dialysis services; and what plans his Department has to ensure that renal service capacity matches both current and projected patient need.

Answered by Karin Smyth - Minister of State (Department of Health and Social Care)

NHS England is delivering a comprehensive programme to improve the diagnosis, treatment, and outcomes of people with kidney disease. In 2023, NHS England published a renal services transformation (RSTP) toolkit to support earlier identification of chronic kidney disease and more joined up services. The RSTP sets out that services, working in partnership with integrated care boards, should undertake capacity planning and activity monitoring to ensure service capacity matches demand requirements.

These changes are intended to make it easier to deliver improvements along the whole patient pathway including earlier diagnosis and treatment, that can potentially prevent or delay the need for dialysis and transplant further downstream in the pathway.

NHS England is also investing in home dialysis for children, supported by a robust network of nurses and clinicians who can move that care from hospital to home. This approach is working, with rates of home dialysis ranging from 64 % to 76% across the 10 National Health Service paediatric dialysis centres.


Written Question
Mental Health Services: Preventive Medicine
Monday 12th January 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of adopting a preventative approach to mental health; and what steps he is taking to support such an approach.

Answered by Zubir Ahmed

The Government’s 10-Year Health Plan sets out ambitious plans to transform mental health services. We want to promote good mental health and wellbeing for the nation, prevent people from developing mental health problems, and improve the lives of people living with a mental health condition. This includes providing mental health support teams in schools and colleges, improving assertive outreach, investing in mental health emergency departments, and increasing access to evidence-based digital interventions.

Additionally, the Office for Health Improvement and Disparities Regional Public Health team work closely with local councils to become signatories to the Prevention Concordat for Better Mental Health. This includes developing local plans to improve mental wellbeing across the life course and to reduce inequalities in mental health, working with partners across the health and care system, as well as schools and employers.

The Government has also recently launched an independent review into prevalence and support for mental health conditions, attention deficit hyperactivity disorder, and autism. This review will seek to identify opportunities to provide different models of support and pathways, within and beyond the National Health Service, that promote prevention and early intervention.


Written Question
Mental Health Services: Men
Monday 12th January 2026

Asked by: Martin Vickers (Conservative - Brigg and Immingham)

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure that men can access timely support for their mental health.

Answered by Zubir Ahmed

The 10-Year Health Plan sets out ambitious plans to boost mental health support across the country. This includes transforming mental health services into 24/7 neighbourhood mental health centres, improving assertive outreach and access to timely mental health care, expanding talking therapies, and giving patients better access to 24/7 support directly through the NHS App. These services are available to men.

The Suicide Prevention Strategy for England, published in 2023, identifies middle aged men as a priority group for targeted and tailored support at a national level.

On 19 November 2025, to coincide with International Men’s Health Day, we published the Men’s Health Strategy. The strategy includes tangible actions to improve access to healthcare, provide the right support to enable men to make healthier choices, develop healthy living and working conditions, foster strong social, community and family networks and address societal norms. It also considers how to prevent and tackle the biggest health problems affecting men of all ages, which include mental health and suicide prevention, respiratory illness, prostate cancer, and heart disease.

Through the Men’s Health Strategy, we are launching a groundbreaking partnership with the Premier League to tackle male suicide and improve mental health literacy, by embedding health messaging into the matchday experience.

We also announced the Suicide Prevention Support Pathfinders programme for middle-aged men. This program will invest up to £3.6 million over three years in areas of England where middle-aged men are at most risk taking their own lives and will tackle the barriers that they face in seeking support.